Clean Science looks like he chemical industry’s overachieving school topper: world #1 in multiple niche chemicals, 40%+ EBITDA margins, and a capex pipeline shinier than a new iPhone. But last month, the promoters sold ~24% stake (oops trade + broker error excuse), and the stock tanked 20% in three months. So now the topper is standing outside class, looking embarrassed, while classmates (Deepak Nitrite, Navin Fluorine) gossip.
2. Introduction
Founded in 2003, Clean Science has become the poster child of Indian specialty chemicals: high-margin, IP-driven, debt-free, and export-heavy. They don’t do “bulk commodity chemicals” like other players. Instead, they make tiny but critical molecules that quietly sit inside diapers, sun creams, and cough syrups.
The product list sounds like chemistry lab viva torture: MEHQ, BHA, TBHQ, AP, Guaiacol, 4-MAP, Anisole. But behind the jargon, they’re basically selling “diaper stoppers, food preservatives, and pharma molecules” at monopoly pricing.
Margins are juicy (40%+), ROE at 22%, and ROCE at 29%. But stock trades at P/E 42, P/B 8.5, EV/EBITDA 28 — basically, you’re paying Starbucks price for cutting chai. And now promoter selling adds masala to investor stress.
Would you pay premium for a chemical stock when promoters themselves are cashing out?
3. Business Model – WTF Do They Even Do?
Think of Clean Science as India’s “chemical Switzerland” — tiny, niche, global leader in obscure molecules.
Performance Chemicals (69%):
MEHQ → prevents diapers from exploding.
BHA → food/feed antioxidant.
TBHQ → stabilizes edible oils.
AP → cosmetics + infant cereals.
HALS → UV stabilizers for plastics, water treatment.
Pharma/Agro Intermediates (19%):
Guaiacol → cough syrups + vanillin.
DCC & DHDT → reagents for anti-retrovirals.
FMCG Chemicals (12%):
4-MAP → sunscreen.
Anisole → perfumes, insect pheromones.
Global market rank: mostly #1, sometimes #2. India’s answer to “we also make world-class stuff.”
4. Financials Overview
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
₹220 Cr
₹217 Cr
₹245 Cr
+1.2%
-10.2%
EBITDA
₹101 Cr
₹98 Cr
₹105 Cr
+3.1%
-3.8%
PAT
₹76.6 Cr
₹72 Cr
₹79 Cr
+6.1%
-3.0%
EPS (₹)
7.2
6.8
7.4
+6.1%
-2.7%
Commentary: Growth flatter than Pepsi after 2 days in fridge. Margins intact, but topline stalling.
5. Valuation – Fair Value Range Only
P/E Method: EPS TTM ₹27.9. Industry P/E ~33. Fair P/E 30–35 → Range ₹837 – ₹977.
EV/EBITDA: EV ₹12,420 Cr; EBITDA TTM ~₹442 Cr → EV/EBITDA = 28. Sector trades ~20–25. Fair range ₹885 – ₹1,100.
DCF (simplified): Assume 15% PAT CAGR for 5 years, 6% terminal, cost of equity 12%. Fair ~₹950 – ₹1,150.
👉 Fair Value Range = ₹850 – ₹1,150. CMP ₹1,172 already above range. Disclaimer: Educational only, not investment advice.
6. What’s Cooking – News, Triggers, Drama
Promoter Sale (Aug’25): 24% stake dumped (error + partial OFS excuse). Holding now ~51%. Investors spooked — “if you don’t trust yourself, why should we?”
